Cerulean Pharmaceuticals Receives $24,000,000 Series C Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=eaf93f3e-e87b-4ae3-967b-941ff461dc70&Preview=1 -
Date
11/15/2010 -
Company Name
Cerulean Pharmaceuticals -
Mailing Address
840 Memorial Drive 5th Floor Cambridge, MA 02139 -
Company Description
Within the field of nanopharmaceuticals, Cerulean Pharma is uniquely focused on a next-generation approach we call Nanobiology. Cerulean’s nanobiology-based drug development is based on a deep understanding of the complex biological microenvironment of human disease combined with engineering therapies on a nanoscale, enabling the creation of breakthrough drugs that optimally target the root causes of disease. -
Website
http://www.ceruleanrx.com -
Transaction Type
Venture Equity -
Transaction Amount
$24,000,000 -
Transaction Round
Series C -
Proceeds Purposes
Cerulean plans to use the capital to advance its CRLX101development candidate into a randomized Phase II trial as a non-small cell lung cancer drug. -
M&A Terms
-
Venture Investor
Lilly Ventures -
Venture Investor
Polaris Venture Partners -
Venture Investor
Venrock -
Venture Investor
Lux Capital -
Venture Investor
Bessemer Venture Partners
